Agios Pharmaceuticals

Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic disorders of metabolism, which are a subset of orphan genetic metabolic diseases. Metabolism is a complex biological process involving the uptake and assimilation of nutrients in cells to produce energy and facilitate many of the processes required for cellular division and growth. We believe that dysregulation of normal cellular metabolism plays a crucial role in many diseases, including certain cancers and rare diseases Agios is a first mover in using cellular metabolism, an unexploited area of biological research with disruptive potential, as a platform for developing potentially transformative medicines. We intend to apply our deep understanding of metabolism, coupled with our ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and rare genetic disorders of metabolism are treated.
Company Growth (employees)
Cambridge, US
Size (employees)
287 (est)+38%
Agios Pharmaceuticals was founded in 2008 and is headquartered in Cambridge, US

Agios Pharmaceuticals Office Locations

Agios Pharmaceuticals has an office in Cambridge
Cambridge, US (HQ)
88 Sidney St

Agios Pharmaceuticals Metrics

Agios Pharmaceuticals Financial Metrics

Revenue (2016)

$69.9 m

Revenue growth (2015-16), %


Net income (2016)

($198.5 m)

Market capitalization (21-Mar-2017)

$2.3 b

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$160.8 m
Agios Pharmaceuticals's current market capitalization is $2.3 b.
Agios Pharmaceuticals's revenue was reported to be $69.9 m in 2016
FY, 2013FY, 2014FY, 2015Y, 2016


$25.5 m$65.4 m$59.1 m$69.9 m

Revenue growth, %


Operating expense total

$64.4 m$119.5 m$177.8 m$270.9 m


($38.9 m)($54.1 m)($118.7 m)($201 m)

EBIT margin, %


Interest income

$55 k$203 k$968 k$2.5 m

Pre tax profit

($117.7 m)($198.5 m)

Income tax expense

$579 k($426 k)($426 k)

Net Income

($39.4 m)($53.5 m)($117.7 m)($198.5 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$71.6 m$14 m$71.8 m$160.8 m

Accounts Receivable

$2.3 m


$2.5 m$4.8 m$8.7 m$10.3 m

Current Assets

$169.7 m$359.5 m$337.3 m$559.9 m


$3.8 m$6.4 m$23.2 m$25.3 m

Total Assets

$201.2 m$491.9 m$420.1 m$619.1 m

Accounts Payable

$3.7 m$11.1 m$14.7 m$17.1 m

Current Liabilities

$36.9 m$61.1 m$52.9 m$88.4 m

Preferred Stock

Additional Paid-in Capital

$244.9 m$591.3 m$630.1 m$842 m

Retained Earnings

($113.4 m)($166.9 m)($284.7 m)($483.2 m)

Total Equity

$131.5 m$424.4 m$345.1 m$358.6 m

Financial Leverage

1.5 x1.2 x1.2 x1.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($39.4 m)($53.5 m)($117.7 m)($198.5 m)

Depreciation and Amortization

$1.4 m$1.4 m$3.3 m$5.7 m

Accounts Receivable

($2.3 m)($1 m)


Accounts Payable

$30 k$7.6 m$4.2 m$3.5 m

Cash From Operating Activities

($56.4 m)($59.4 m)($76.9 m)$38.6 m

Purchases of PP&E

($1.3 m)($2.2 m)($20.2 m)($9.9 m)

Cash From Investing Activities

($87.2 m)($333.3 m)$128.3 m($119.4 m)

Cash From Financing Activities

$123.9 m$335.2 m$6.4 m$169.8 m

Income Taxes Paid

$6 m$6 m$6 m

Agios Pharmaceuticals Market Value History

Agios Pharmaceuticals Job Categories

Agios Pharmaceuticals News

Agios Pharmaceuticals Company Life

You may also be interested in